Femasys Inc 8-K Filing
Ticker: FEMY · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1339005
| Field | Detail |
|---|---|
| Company | Femasys Inc (FEMY) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $12 Million, $58 Million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Femasys Inc (ticker: FEMY) to the SEC on Nov 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share FEMY The Nasdaq Stock Mar); $12 Million (o Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58); $58 Million (lion Financing, with Potential to Reach $58 Million. A copy of the press release is being f).
How long is this filing?
Femasys Inc's 8-K filing is 2 pages with approximately 453 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-11-03 09:19:40
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share FEMY The Nasdaq Stock Mar
- $12 Million — o Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58
- $58 Million — lion Financing, with Potential to Reach $58 Million. A copy of the press release is being f
Filing Documents
- ef20058162_8k.htm (8-K) — 33KB
- ef20058162_ex99-1.htm (EX-99.1) — 22KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-25-040104.txt ( ) — 196KB
- femy-20251103.xsd (EX-101.SCH) — 4KB
- femy-20251103_lab.xml (EX-101.LAB) — 22KB
- femy-20251103_pre.xml (EX-101.PRE) — 16KB
- ef20058162_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On November 3, 2025, Femasys Inc. (the "Company") issued a press release announcing that Femasys Secures FDA Approval to Advance Final FemBloc Trial Phase and $12 Million Financing, with Potential to Reach $58 Million. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Femasys Inc. dated November 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Femasys Inc. By: /s/ Kathy Lee-Sepsick Names: Kathy Lee-Sepsick Title: Chief Executive Officer Date: November 3, 2025